drugset
drugset / Trial / NCT02461407

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

NCT02461407 ↗

Phase 2/3 Unknown 378 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Gastric Cancer.

Timeline

Start
2015-06
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule — Oral

Indications

gastric cancer